U.S.-China biotech competition

Former FDA commissioners say China's scientific progress and faster trial start-up speed are driving more Phase 1 trials there than in the U.S.

Two former commissioners, writing before Heidi Overton's Senate hearing on Thursday, argue that FDA review capacity now decides where new medicines reach patients first. Their evidence is a count of trial starts.